Please enable JavaScript to continue using this application.

Compare $RARE vs $XNCR | Chartloom

Compare

$RARE vs $XNCR

Ultragenyx Pharmaceutical Inc · Xencor Inc

RARE

Ultragenyx Pharmaceutical Inc

XNCR

Xencor Inc

Compare $RARE vs $XNCR

Comparing Ultragenyx Pharmaceutical Inc and Xencor Inc

RAREUltragenyx Pharmaceutical Inc

XNCRXencor Inc

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

XNCRXencor Inc

Market cap

$1.83B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.26x

Rev growth (TTM)

-33.2%

YTD performance

65.1%

52W performance

98.6%

FCF yield

-11.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RARE

XNCR

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

XNCR

Xencor Inc

Market Cap

RARE$1.52B

XNCR$1.83B

Enterprise Value

RARE$2.54B

XNCR$1.89B

Price

RARE$15.48

XNCR$24.63

P/E Ratio

RAREN/A

XNCRN/A

P/S Ratio

RARE2.13x

XNCR17.40x

EV/Sales

RARE3.54x

XNCR17.97x

EV/EBITDA

RARE0.00x

XNCR31.73x

P/B Ratio

RARE163.83x

XNCR3.71x

P/FCF Ratio

RAREN/A

XNCRN/A

EV/FCF

RARE-5.14x

XNCR-9.06x

PEG Ratio

RAREN/A

XNCRN/A

Forward P/E (NTM)

RAREN/A

XNCRN/A

Forward P/S (NTM)

RARE1.74x

XNCR14.26x

Revenue (TTM)

RARE$717M

XNCR$105M

Revenue Growth (YoY)

RARE17.5%

XNCR-33.2%

Forward Rev Growth

RARE27.7%

XNCR7.4%

Gross Margin (TTM)

RARE83.1%

XNCR0.0%

Operating Margin (TTM)

RARE0.0%

XNCR0.0%

EBITDA Margin (TTM)

RARE-69.0%

XNCR-188.5%

Net Margin (TTM)

RARE-81.7%

XNCR-155.6%

FCF Margin (TTM)

RARE-68.9%

XNCR-198.4%

Net Income (TTM)

RARE$-586M

XNCR$-163M

FCF (TTM)

RARE$-494M

XNCR$-208M

EPS (TTM)

RARE-$5.75

XNCR-$2.15

ROE (TTM)

RARE-41417.0%

XNCR-2866.0%

ROA (TTM)

RARE-4437.0%

XNCR-2038.0%

ROIC (TTM)

RARE-5861.0%

XNCR-2379.0%

Cash

RARE$125M

XNCR$45M

Debt

RARE$1.14B

XNCR$105M

Net Cash/Debt

RARE$-1.02B

XNCR$-60M

Current Ratio (TTM)

RARE1.73x

XNCR6.39x

Quick Ratio (TTM)

RARE1.43x

XNCR6.09x

Debt/Equity (TTM)

RARE90.54x

XNCR0.21x

Debt/Assets (TTM)

RARE0.0%

XNCR0.0%

Interest Coverage (TTM)

RAREN/A

XNCRN/A

Net Debt/EBITDA (TTM)

RARE0.00x

XNCR0.00x

Beta

RARE0.35

XNCR0.81

52W Performance

RARE-49.8%

XNCR98.6%

YTD Performance

RARE-34.4%

XNCR65.1%

% from 52W High

RARE-61.2%

XNCR-19.5%

% from 52W Low

RARE21.6%

XNCR137.4%

Asset Turnover (TTM)

RARE0.54x

XNCR0.13x

FCF Yield (TTM)

RARE-32.4%

XNCR-11.4%

Earnings Yield (TTM)

RARE-38.4%

XNCR-8.9%

Dividend Yield (TTM)

RAREN/A

XNCRN/A

Rule of 40

RARE-51.4

XNCR-231.6

EV/GP/RG

RARE0.17

XNCRN/A

Ticker research

View RARE research View XNCR research

Metric	RARE Ultragenyx Pharmaceutical Inc	XNCR Xencor Inc
Market & Valuation
Market Cap	$1.52B	$1.83B
Enterprise Value	$2.54B	$1.89B
Price	$15.48	$24.63
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	17.40x
EV/Sales	3.54x	17.97x
EV/EBITDA	0.00x	31.73x
P/B Ratio	163.83x	3.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-9.06x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	14.26x
Revenue & Growth
Revenue (TTM)	$717M	$105M
Revenue Growth (YoY)	17.5%	-33.2%
Forward Rev Growth	27.7%	7.4%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-188.5%
Net Margin (TTM)	-81.7%	-155.6%
FCF Margin (TTM)	-68.9%	-198.4%
Net Income (TTM)	$-586M	$-163M
FCF (TTM)	$-494M	$-208M
EPS (TTM)	-$5.75	-$2.15
ROE (TTM)	-41417.0%	-2866.0%
ROA (TTM)	-4437.0%	-2038.0%
ROIC (TTM)	-5861.0%	-2379.0%
Financial Health
Cash	$125M	$45M
Debt	$1.14B	$105M
Net Cash/Debt	$-1.02B	$-60M
Current Ratio (TTM)	1.73x	6.39x
Quick Ratio (TTM)	1.43x	6.09x
Debt/Equity (TTM)	90.54x	0.21x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	0.81
52W Performance	-49.8%	98.6%
YTD Performance	-34.4%	65.1%
% from 52W High	-61.2%	-19.5%
% from 52W Low	21.6%	137.4%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.13x
FCF Yield (TTM)	-32.4%	-11.4%
Earnings Yield (TTM)	-38.4%	-8.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-231.6
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View XNCR research

Valuation

P/S Ratio

RARE

2.13x

XNCR

17.40x

EV/FCF

XNCR

-9.06x

RARE

-5.14x

Growth & revenue

Revenue Growth TTM

RARE

17.5%

XNCR

-33.2%

Forward Revenue Growth

RARE

27.7%

XNCR

7.4%

Profitability & performance

Gross Margin

RARE

83.1%

XNCR

0.0%

ROE

XNCR

-2866.0%

RARE

-41417.0%

FCF Yield %

XNCR

-11.4%

RARE

-32.4%

52-Week Performance

XNCR

98.6%

RARE

-49.8%

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

XNCR

Xencor Inc

Market Cap

RARE$1.52B

XNCR$1.83B

Enterprise Value

RARE$2.54B

XNCR$1.89B

Price

RARE$15.48

XNCR$24.63

P/E Ratio

RAREN/A

XNCRN/A

P/S Ratio

RARE2.13x

XNCR17.40x

EV/Sales

RARE3.54x

XNCR17.97x

EV/EBITDA

RARE0.00x

XNCR31.73x

P/B Ratio

RARE163.83x

XNCR3.71x

P/FCF Ratio

RAREN/A

XNCRN/A

EV/FCF

RARE-5.14x

XNCR-9.06x

PEG Ratio

RAREN/A

XNCRN/A

Forward P/E (NTM)

RAREN/A

XNCRN/A

Forward P/S (NTM)

RARE1.74x

XNCR14.26x

Revenue (TTM)

RARE$717M

XNCR$105M

Revenue Growth (YoY)

RARE17.5%

XNCR-33.2%

Forward Rev Growth

RARE27.7%

XNCR7.4%

Gross Margin (TTM)

RARE83.1%

XNCR0.0%

Operating Margin (TTM)

RARE0.0%

XNCR0.0%

EBITDA Margin (TTM)

RARE-69.0%

XNCR-188.5%

Net Margin (TTM)

RARE-81.7%

XNCR-155.6%

FCF Margin (TTM)

RARE-68.9%

XNCR-198.4%

Net Income (TTM)

RARE$-586M

XNCR$-163M

FCF (TTM)

RARE$-494M

XNCR$-208M

EPS (TTM)

RARE-$5.75

XNCR-$2.15

ROE (TTM)

RARE-41417.0%

XNCR-2866.0%

ROA (TTM)

RARE-4437.0%

XNCR-2038.0%

ROIC (TTM)

RARE-5861.0%

XNCR-2379.0%

Cash

RARE$125M

XNCR$45M

Debt

RARE$1.14B

XNCR$105M

Net Cash/Debt

RARE$-1.02B

XNCR$-60M

Current Ratio (TTM)

RARE1.73x

XNCR6.39x

Quick Ratio (TTM)

RARE1.43x

XNCR6.09x

Debt/Equity (TTM)

RARE90.54x

XNCR0.21x

Debt/Assets (TTM)

RARE0.0%

XNCR0.0%

Interest Coverage (TTM)

RAREN/A

XNCRN/A

Net Debt/EBITDA (TTM)

RARE0.00x

XNCR0.00x

Beta

RARE0.35

XNCR0.81

52W Performance

RARE-49.8%

XNCR98.6%

YTD Performance

RARE-34.4%

XNCR65.1%

% from 52W High

RARE-61.2%

XNCR-19.5%

% from 52W Low

RARE21.6%

XNCR137.4%

Asset Turnover (TTM)

RARE0.54x

XNCR0.13x

FCF Yield (TTM)

RARE-32.4%

XNCR-11.4%

Earnings Yield (TTM)

RARE-38.4%

XNCR-8.9%

Dividend Yield (TTM)

RAREN/A

XNCRN/A

Rule of 40

RARE-51.4

XNCR-231.6

EV/GP/RG

RARE0.17

XNCRN/A

Ticker research

View RARE research View XNCR research

Metric	RARE Ultragenyx Pharmaceutical Inc	XNCR Xencor Inc
Market & Valuation
Market Cap	$1.52B	$1.83B
Enterprise Value	$2.54B	$1.89B
Price	$15.48	$24.63
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	17.40x
EV/Sales	3.54x	17.97x
EV/EBITDA	0.00x	31.73x
P/B Ratio	163.83x	3.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-9.06x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	14.26x
Revenue & Growth
Revenue (TTM)	$717M	$105M
Revenue Growth (YoY)	17.5%	-33.2%
Forward Rev Growth	27.7%	7.4%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-188.5%
Net Margin (TTM)	-81.7%	-155.6%
FCF Margin (TTM)	-68.9%	-198.4%
Net Income (TTM)	$-586M	$-163M
FCF (TTM)	$-494M	$-208M
EPS (TTM)	-$5.75	-$2.15
ROE (TTM)	-41417.0%	-2866.0%
ROA (TTM)	-4437.0%	-2038.0%
ROIC (TTM)	-5861.0%	-2379.0%
Financial Health
Cash	$125M	$45M
Debt	$1.14B	$105M
Net Cash/Debt	$-1.02B	$-60M
Current Ratio (TTM)	1.73x	6.39x
Quick Ratio (TTM)	1.43x	6.09x
Debt/Equity (TTM)	90.54x	0.21x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	0.81
52W Performance	-49.8%	98.6%
YTD Performance	-34.4%	65.1%
% from 52W High	-61.2%	-19.5%
% from 52W Low	21.6%	137.4%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.13x
FCF Yield (TTM)	-32.4%	-11.4%
Earnings Yield (TTM)	-38.4%	-8.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-231.6
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View XNCR research